Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK‐1) receptor antagonist, serlopitant, for the treatment of pruritus (itch) associated with atopic dermatitis and for the treatment of pruritus following burn injury. The ATOMIK study, MTI‐103, is a multi‐center, randomized, placebo‐controlled study … Read More

Menlo Therapeutics Inc. (Menlo Park, CA) announced today that the phase 2 trial (TCP-102) evaluating serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis successfully met its primary efficacy endpoint and key secondary endpoints, demonstrating a statistically significant reduction in pruritus (p<0.001 for the primary efficacy analysis at … Read More

Menlo Therapeutics Inc., a clinical stage pharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant, VPD-737) for the treatment of pruritus (itch).  Over the past 16 months, Menlo Therapeutics established direct operations to advance serlopitant and recruited an experienced drug development management team including: Steven Basta, CEO. Mr. … Read More

MENLO PARK, Calif., Aug. 10, 2016 /PRNewswire/ — Menlo Therapeutics Inc., (Menlo Park, CA) announced today that it has entered into an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) for the development and commercialization of serlopitant in Japan. Serlopitant is a first–in-class, once-daily oral NK-1 receptor … Read More